Wegovy

Wegovy is a once-weekly injectable medication containing semaglutide, manufactured by Novo Nordisk and clinically proven to support significant weight loss. It works by mimicking the GLP-1 hormone, which reduces appetite, slows digestion, and helps you feel full for longer. At Pharmacy Weight Loss Norland clinic, Wegovy is prescribed as part of a structured weight loss programme.

The starting dose of Wegovy 0.25mg, used during weeks 1 to 4, costs £69.00 per month at Pharmacy Weight Loss Norland clinic. This introductory dose allows your body to adjust to semaglutide before the dose is gradually increased. It is the most affordable entry point into the Wegovy treatment plan.

The full maintenance dose of Wegovy 2.4mg, reached from week 17 onwards, costs £179.00 per month at Pharmacy Weight Loss Norland clinic. This is the target dose where most patients achieve their greatest weight loss results. Your prescriber will only progress you to this dose once lower doses have been tolerated well.

Yes, Wegovy is a prescription-only medication and cannot be dispensed without a valid prescription issued by a qualified prescriber. At Pharmacy Weight Loss Norland clinic, an online consultation is completed before any prescription is approved. This ensures Wegovy is safe and appropriate for you before treatment begins.

Most patients begin to notice reduced appetite and early weight loss within the first two to four weeks of starting Wegovy. Clinical trials show that significant weight loss typically builds over the first 16 to 20 weeks as the dose is gradually increased to 2.4mg. Results vary between individuals depending on lifestyle factors alongside the treatment.

Yes, Pharmacy Weight Loss Norland clinic offers delivery of Wegovy directly to your home address in Norland and the surrounding areas. All orders are dispatched in discreet, temperature-appropriate packaging to maintain the integrity of the semaglutide injection. Delivery timescales will be confirmed at the point of ordering.

The most common side effects of Wegovy include nausea, vomiting, diarrhoea, constipation, and stomach discomfort, particularly during the dose escalation phase. These effects are usually mild to moderate and tend to improve as your body adjusts to semaglutide. Your prescriber at Pharmacy Weight Loss Norland clinic can advise on managing side effects if they persist.

To be eligible for Wegovy at Pharmacy Weight Loss Norland clinic, you generally need a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related health condition such as type 2 diabetes or high blood pressure. Wegovy is not suitable for everyone, including those who are pregnant or have a personal or family history of medullary thyroid cancer. A full eligibility assessment is completed during your online consultation.

Wegovy contains semaglutide at a licensed dose of up to 2.4mg specifically approved for weight management, making it distinct from Ozempic which uses a lower semaglutide dose intended for type 2 diabetes. Compared to other GLP-1 treatments, Wegovy has the largest body of clinical evidence for weight loss, with trials showing an average of around 15% body weight reduction. Pharmacy Weight Loss Norland clinic can help you determine which treatment is most suitable for your individual needs.

Wegovy is administered as a subcutaneous injection once weekly, using a pre-filled pen device that is designed to be simple to use at home. The injection is typically given into the abdomen, thigh, or upper arm on the same day each week. Full instructions and guidance are provided when you order through Pharmacy Weight Loss Norland clinic.

The Wegovy dose escalation schedule starts at 0.25mg for the first four weeks and gradually increases every four weeks up to the 2.4mg maintenance dose from week 17 onwards. This gradual increase is essential to minimise side effects such as nausea and to allow your body to adapt to semaglutide. Pharmacy Weight Loss Norland clinic prescribes Wegovy following this schedule to ensure your treatment is both safe and effective.

Clinical studies show that patients who stop taking Wegovy tend to regain a significant portion of lost weight, which is why Novo Nordisk designed it as a long-term treatment rather than a short course. Most prescribers recommend continuing Wegovy for at least 12 to 16 months to achieve and consolidate meaningful weight loss. At Pharmacy Weight Loss Norland clinic, your ongoing treatment and progress are reviewed regularly to support long-term outcomes.